Loading
A phase 1 trial of PoMA sonodynamic therapy run by Alpheus Medical, Inc., completed.
Study to Evaluate 5-ALA Combined With CV01 Delivery of Ultrasound in Recurrent High Grade Glioma is a phase 1 interventional study registered as NCT05362409 by Alpheus Medical, Inc., with 22 participants enrolled, started 2022-06-29, primary completion reached 2024-12-03. Conditions recorded: High Grade Glioma. Interventions recorded: 5 Aminolevulinic Acid, CV01-delivered ultrasound.
Shares PoMA sonodynamic therapy, Alpheus Medical and the tag pipeline.
Shares PoMA sonodynamic therapy, Alpheus Medical and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/